Sign in Subscribe
Class action lawsuits

Hims & Hers Health, Inc. Class Action Lawsuit Update: Lead Plaintiff Deadline Approaches

Strategic Insights

— 1 min read

The Rosen Law Firm, a global investor rights law firm, reminds investors who purchased common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025, and June 23, 2025, that they may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The firm filed a class action lawsuit on behalf of investors who suffered losses due to the company's alleged misrepresentations about its partnership with Novo Nordisk A/S and its access to the weight-loss drug Wegovy.

Key Takeaways:

  • The class action lawsuit was filed on behalf of investors who purchased Hims common stock between April 29, 2025, and June 23, 2025, and who may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
  • The lawsuit alleges that the defendants made false and misleading statements and/or failed to disclose material information about the company's partnership with Novo Nordisk A/S and its access to the weight-loss drug Wegovy.
  • The lead plaintiff deadline is August 25, 2025, and investors who wish to serve as lead plaintiff must move the Court by this date.
  • The Rosen Law Firm has a proven track record of success in leadership roles and has represented investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • The firm achieved the largest ever securities class action settlement against a Chinese Company at the time and has been ranked in the top 4 each year since 2013.
  • The lawsuit alleges that the defendants made false and misleading statements and/or failed to disclose that the communication between Hims and Novo Nordisk A/S would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers.
  • The lawsuit also alleges that the defendants made positive statements about the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products.

Statistics:

  • The class period for the lawsuit is April 29, 2025, to June 23, 2025.
  • The lead plaintiff deadline is August 25, 2025.
  • The Rosen Law Firm has secured over $438 million for investors in 2019.
  • In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar.

Sources:

  • Rosen Law Firm (NY)
  • New York, NY (via Newsfile Corp. - July 22, 2025)

Read more